Literature DB >> 7230242

Clinical use of minoxidil (Loniten).

A M Joekes, F D Thompson, P F O'Regan.   

Abstract

The powerful peripheral vasodilator minoxidil, in a dose of 5-40 mg daily, controlled the previously refractory blood pressure in 45 out of 47 patients for periods up to fifty-seven months. The majority of the previous polypharmacy was withdrawn, leaving most of the patients taking a beta-blocking drug, minoxidil and a diuretic. Severe sodium retention leading to congestive cardiac failure necessitated the withdrawal of the drug in 3 patients. In one patient the drug was discontinued because of postural hypotension, and it was withdrawn in 2 female patients because of hirsutism. Five patients were removed from the trial as they were started on chronic maintenance haemodialysis or received a renal transplant. Significant glucose intolerance developed in one patient, requiring the addition of an oral hypoglycaemic agent. The 4 deaths that occurred were not directly related to treatment. Following the oral administration of 5 mg minoxidil, an obvious reduction in both the systolic and diastolic pressure was seen in two hours.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7230242      PMCID: PMC1438391          DOI: 10.1177/014107688107400408

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  2 in total

1.  Pharmacologic properties of minoxidil: a new hypotensive agent.

Authors:  D W DuCharme; W A Freyburger; B E Graham; R G Carlson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

2.  Pharmacokinetic studies of minoxidil.

Authors:  T B Gottlieb; R C Thomas; C A Chidsey
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

  2 in total
  2 in total

1.  Could Topical Minoxidil Cause Non-Arteritic Anterior Ischemic Optic Neuropathy?

Authors:  Habibullah Aktas; Sevil Alan; Elif Betül Türkoglu; Özge Sevik
Journal:  J Clin Diagn Res       Date:  2016-08-01

2.  Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Gary Duncan; Karl Firth; Vinoj George; Minh Duc Hoang; Andrew Staniforth; Godfrey Smith; Chris Denning
Journal:  Stem Cells Dev       Date:  2017-10-09       Impact factor: 3.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.